Anti-Solute Carrier Family 22 Member 5 Antibody
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application
| WB |
---|---|
Primary Accession | Q9Z0E8 |
Host | Rabbit |
Reactivity | Mouse, Rat |
Clonality | Polyclonal |
Format | Lyophilized |
Description | Rabbit IgG polyclonal antibody for Solute carrier family 22 member 5(SLC22A5) detection. Tested with WB in Mouse;Rat. |
Reconstitution | Add 0.2ml of distilled water will yield a concentration of 500ug/ml. |
Gene ID | 20520 |
---|---|
Other Names | Solute carrier family 22 member 5, High-affinity sodium-dependent carnitine cotransporter, Organic cation/carnitine transporter 2, Slc22a5, Octn2 |
Calculated MW | 62780 MW KDa |
Application Details | Western blot, 0.1-0.5 µg/ml, Mouse, Rat |
Subcellular Localization | Apical cell membrane ; Multi-pass membrane protein . Colocalizes with PDZK1 on apical membranes of kidney proximal tubules. |
Tissue Specificity | Widely expressed. Expressed in kidney, liver and testis. . |
Protein Name | Solute carrier family 22 member 5 |
Contents | Each vial contains 5mg BSA, 0.9mg NaCl, 0.2mg Na2HPO4, 0.05mg Thimerosal, 0.05mg NaN3. |
Immunogen | A synthetic peptide corresponding to a sequence at the C-terminus of mouse Solute carrier family 22 member 5(531-547aa KQWQIQSQTRMQKDGEE), different from the related rat sequence by two amino acids. |
Purification | Immunogen affinity purified. |
Cross Reactivity | No cross reactivity with other proteins |
Storage | At -20˚C for one year. After r˚Constitution, at 4˚C for one month. It˚Can also be aliquotted and stored frozen at -20˚C for a longer time.Avoid repeated freezing and thawing. |
Name | Slc22a5 {ECO:0000312|MGI:MGI:1329012} |
---|---|
Function | Sodium-ion dependent, high affinity carnitine transporter. Involved in the active cellular uptake of carnitine. Transports one sodium ion with one molecule of carnitine (PubMed:10454528, PubMed:20722056). Also transports organic cations such as tetraethylammonium (TEA) without the involvement of sodium. Also relative uptake activity ratio of carnitine to TEA is 11.3 (PubMed:10454528). May also contribute to regulate the transport of organic compounds in testis across the blood-testis-barrier (By similarity). |
Cellular Location | Apical cell membrane; Multi-pass membrane protein. Basal cell membrane {ECO:0000250|UniProtKB:O76082}; Multi-pass membrane protein. Cell membrane {ECO:0000250|UniProtKB:O76082}; Multi-pass membrane protein {ECO:0000250|UniProtKB:O76082}. Note=Colocalizes with PDZK1 on apical membranes of kidney proximal tubules (PubMed:15523054) In intestinal cells, apical expression is induced by TNF (PubMed:20722056). |
Tissue Location | Widely expressed. Expressed in kidney, liver and testis (PubMed:11010964). Expressed at the brush border of the small, large intestine and colon (at protein level) (PubMed:11010964, PubMed:20722056). |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Solute carrier family 22(organic cation/carnitine transporter), member 5, also called SLC22A5 or OCTN2 is a membrane transport protein associated with primary carnitine deficiency. This gene is mapped to 5q31.1. Polyspecific organic cation transporters in the liver, kidney, intestine, and other organs are critical for elimination of many endogenous small organic cations as well as a wide array of drugs and environmental toxins. The encoded protein is a plasma integral membrane protein which functions both as an organic cation transporter and as a sodium-dependent high affinity carnitine transporter. The encoded protein is involved in the active cellular uptake of carnitine. Mutations in this gene are the cause of systemic primary carnitine deficiency(CDSP), an autosomal recessive disorder manifested early in life by hypoketotic hypoglycemia and acute metabolic decompensation, and later in life by skeletal myopathy or cardiomyopathy.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.